Paul Geudens

Providing strategic insight and services to Cardiovascular MedTech startups.

📍 Belgium🔄 Updated September 2026💼 2 investments📅 8 years investing🗓 Last invested Mar 2022
Angel investor🌍 Belgium
2
Total investments
0
Early stage
2
Mid stage
0
Late stage
8y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Mar 2022
Neurovascular medtech startup
Investor
Sep 2018
Protembis is an Aachen, Germany based medical device startup. It develops a novel catheter-based filter device for use during cardiac interventions. The device is designed to minimize the risk of stroke and other neurological injury during these interventions – particularly during transcatheter aortic valve replacement procedures (TAVR/ TAVI). The filter blocks embolic debris from entering the blood vessels leading to the brain. The initial safety and feasibility of the ProtEmbo® device has been demonstrated in a first-in-human study in 2017/ 2018. The imaging data of the study suggests that the ProtEmbo® device decreases the risk of brain injury by up to 90%. Protembis has closed an oversubscribed $10M Series A financing round in 2018 and expects to bring its product to market maturity with this round. Therefore the team plans to conduct further clinical studies in heart centers in Europe and the U.S. The ProtEmbo® device is not yet commercially available.
Experience · 3 entries
All (3)
Investments (2)
2022
Investor
Mar 2022
Neurovascular medtech startup
2018
Investor
Sep 2018
Protembis is an Aachen, Germany based medical device startup. It develops a novel catheter-based filter device for use during cardiac interventions. The device is designed to minimize the risk of stroke and other neurological injury during these interventions – particularly during transcatheter aortic valve replacement procedures (TAVR/ TAVI). The filter blocks embolic debris from entering the blood vessels leading to the brain. The initial safety and feasibility of the ProtEmbo® device has been demonstrated in a first-in-human study in 2017/ 2018. The imaging data of the study suggests that the ProtEmbo® device decreases the risk of brain injury by up to 90%. Protembis has closed an oversubscribed $10M Series A financing round in 2018 and expects to bring its product to market maturity with this round. Therefore the team plans to conduct further clinical studies in heart centers in Europe and the U.S. The ProtEmbo® device is not yet commercially available.
2012
Partner and Managing Director
Feb 2012
Founded in February 2012 by ex-J&J Medical Device expert with over 30 years of corporate and start-up experience. Through executive consulting and in-field support, QUARTERBACK CONSULTING helps create a sustainable, attractive platform for Medtech startups in Europe, alleviating many of the roadblocks that are in the way to successful market entry.